• Explore /
  • Poster
  • / IMMUNIB trial (AIO-HEP-0218/ass): A single-arm, phase II study evaluating safety and efficacy of immunotherapy nivolumab in combination with lenvatinib in advanced-stage hepatocellular carcinoma (HCC).

IMMUNIB trial (AIO-HEP-0218/ass): A single-arm, phase II study evaluating safety and efficacy of immunotherapy nivolumab in combination with lenvatinib in advanced-stage hepatocellular carcinoma (HCC).

Abstract Poster

Authors

Arndt Vogel

Arndt Vogel

Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule, Hannover, Germany

Arndt Vogel , Gabriele Margareta Siegler , Jurgen Siebler , Udo Lindig , Michael Schultheiß , Tobias Müller , Henry Simon , Christiane Jöckel , Daniel Wilhelm Mueller , Salah-Eddin Al-Batran , Anna Saborowski , Enrico N De Toni

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT03841201

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 4107)

DOI

10.1200/JCO.2022.40.16_suppl.4107

Abstract #

4107

Poster Bd #

94

Abstract Disclosures

Similar Posters

First Author: Bridget Keenan

First Author: Dale Randall Shepard

First Author: Kazufumi Kobayashi

First Author: Claudia A.M. Fulgenzi